Improved assay for fecal calprotectin

Clinica Chimica Acta

Volumn 292, Issue 1-2, 2000, Pages 41-54

  Tøn, Hege ^a   Brandsnes, Øystein ^a   Dale, Siri ^a   Holtlund, Jostein ^a   Skuibina, Eugenia ^b   Schjønsby, Henning ^c   Johne, Berit ^a  

^a ALTANA PHARMA AG   (Germany)

^b PAREXEL INTERNATIONAL   (United States)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Calprotectin; ELISA; Feces

Indexed keywords

CALCIUM BINDING PROTEIN; CALPROTECTIN;

ACCURACY; ARTICLE; COLITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACTION; FECES ANALYSIS; GASTROINTESTINAL TUMOR; HUMAN; INFLAMMATORY DISEASE; PRIORITY JOURNAL; REPRODUCIBILITY;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MEMBRANE GLYCOPROTEINS; NEURAL CELL ADHESION MOLECULES; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 0033953729     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00206-5     Document Type: Article

References (38)

1. Altman D.G. Practical statistics for medical research. 1996;Chapman and Hall.
2. Berntzen H.B., Fagerhol M.K. L1, a major granulocyte protein; isolation of high quantities of its subunits. Scand. J. Clin. Lab. Invest. 50:(7):1990;769-774.
3. Berntzen H.B., Fagerhol M.K., Østensen M., Mowinckel P., Høyeraal H.M. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J. Rheumatol. 18:1991;133-138.
4. Berntzen H.B., Munthe E., Fagerhol M.K. The major leukocyte protein L1 as an indicator of inflammatory joint disease. Scand. J. Rheumatol. 76:1988;251-256.
5. Brandtzaeg P., Dale I., Fagerhol M.K. Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. 2. Normal and aberrant occurrence in various epithelia. Am J. Clin. Pathol. 87:1987;700-707.
6. Clohessy P.A., Golden B.E. The mechanism of calprotectin's candidastic activity appears to involve zinc chelation. Biochem. Soc. Transactions. 1996;309S.
7. Courtheyn D., Bakeroot V., De-Volder F., Vercammen J. Multi-residue enzyme immunoassays for screening of beta-antagonists in faeces and feeds. Food Agric. Immunol. 6:1994;131-139.
8. Dale I., Brandtzaeg P. Expression of the epithelial L1 antigen as immunohistochemical marker of squamous cell carcinoma of the lung. Histopathology. 14:1989;493-502.
9. Dale I., Brandtzaeg P., Fagerhol M.K., Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Am. J. Clin. Pathol. 84:(1):1985;24-34.
10. Dale I., Fagerhol M.K., Naesgaard I. Purification and partial characterization of a highly immunogenic human leucocyte protein, the L1 antigen. Eur. J. Biochem. 134:(1):1983;1-6.
11. Delabie J., DeWoIf-Peeters C., van den Oord J.J., Desmet V.J. Differential expression of the calcium-binding proteins MRP8 and MRP14 in granulomatous conditions. An immunohistochemical study. Clin. Exp. Immunol. 81:(1):1990;123-126.
12. Dunlop O., Bruun J.N., Myrvang B., Fagerhol M.K. Calprotectin in cerebrospinal fluid of the HIV infected: A diagnostic marker of opportunistic central nervous system infection? Scand. J. Infect. Dis. 23:(6):1991;687-689.
13. Fagerhol M.K., Andersson K.B., Naess-Andresen C.F., Brandtzaeg P., Dale I. Calprotectin (the L1 leukocyte protein). Smith V.L., Dedman J.R. Stimulus response coupling: the role of intracellular calcium-binding proteins. 1990;187-210 CRC Press.
14. Fagerhol M.K., Dale I., Anderson I. Release and quantitation of a leucocyte derived protein (L1). Scand. J. Haematol. 24:1980;393-398.
15. Gilbert J.A., Ahlquist A.A., Mahoney D.W., Zinsmeister A.R., Rubin J., Ellefson R.D. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand. J. Gastroenterol. 31:1996;1001-1005.
16. Guerrant R.L., Araujo V., Soares E., Kotloff K., Lima A.A.M., Cooper W.H., et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J. Clin. Microbiol. 30:1992;1238-1242.
17. Guerrant R.L., Zaenker E.I., Choi S.W., Park C.H. Fecal lactoferrin screening assay for inflammatory bacterial diarrhea - Reply. J. Clin. Microbiol. 34:(9):1996;2337-2338.
18. Johne B., Fagerhol M.K., Lyberg T., Prydz H., Brandtzaeg P., Naess-Andresen C.F. Functional and clinical aspects of the myelomonocytic protein calprotectin. J. Clin. Molecular Pathol. 50:1997;113-123.
19. Kristinsson J., Røseth A., Fagerhol M.K., Aadland E., Schønsby H., Børmer O., et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis. Colon Rectum. 1998;316-321.
20. Kristinsson J, Nygaard K, Armbruster C, Ugstad M, Tøn H, Fuglerud P et al. Fecal calprotectin levels in colorectal cancer, measured with a new simplified method. Poster presented at World Congress of Gastroenterology, Vienna, 1998.
21. 1-antitrypsin in patients with Crohn's disease. A comparison of nephelometry and radial immunodiffusion. Dig. Dis. Sci. 39:1994;507-512.
22. Meling T., Aabakken L., Røseth A., Osnes M. Faecal calprotectin-shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand. J. Gastroenterol. 31:1996;339-344.
23. Naess-Andresen C.F., Egelandsdal B., Fagerhol M.K. Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein). J Clin Path, Clin Mol Pathol. Oct 48(5):1995;M278-M284.
24. Owen R.W., Weisgerber U.M., Carr J., Harrison M.H. Analysis of calcium-lipid complexes in faeces. Eur. J. Cancer Prevention. 4:1995;247-255.
25. Ravel R. Various factors affecting laboratory test interpretation. Ravel R. Clinical laboratory medicine. 1995;1-8 Mosby-Year Book, St. Louis, MI.
26. Røseth A.G., Fagerhol M.K., Aadland E., Schønsby H. Assessment of the neutrophil-dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol. 27:(9):1992;793-798.
27. Røseth A.G., Kristinsson J., Fagerhol M.K., Aadland E., Schjønsby H., Nygaard K., et al. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand. J. Gastroenterology. 28:(12):1993;1073-1076.
28. Røseth A.G., Kristinsson J., Schønsby H., Nygaard K., Raknerud N., Fagerhol M.K., et al. Faecal calprotectin in a consecutive series of outpatients referred for colonoscopy, with special emphasis on inflammatory bowel disease and colorectal neoplasia. Digestion. 1996.
29. Røseth A.G., Aadland E., Jahnsen J., Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;176-180.
30. Schmidt P.N., Blimp-Jensen S., Svendsen P.J., Wandall J.H. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand. J. Clin. Lab. Invest. 55:1995;35-45.
31. Silletti R.P., Lee G., Ailey E. Role of stool screening tests in diagnosis of inflammatory bacterial enteritis and in selection of specimens likely to yield invasive enteric pathogens. J. Clin. Microbiol. 34:1996;1161-1165.
32. Sohnle P.G., Collins-Lech C., Wiessner J.H. Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J. Infect. Dis. 163:1991;187-192.
33. Sohnle P.G., Collins-Lech C., Wiessner J.H. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J. Infect. Dis. 164:1991;137-142.
34. Sorg C. The calcium binding proteins MRP8 and MRP14 in acute and chronic inflammation. Behringer Inst. Mitt. 91:1992;126-137.
35. Steinbakk M., Naess-Andresen C.-F., Lingaas E., Dale I., Brandtzaeg P., Fagerhol M.K. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 336:(8718):1990;763-765.
36. Van-den-Berg J.W.O., Edixhoven-Bosdijk A., Koole-Lesius R., Wilson J.H.P. Faecal haem assay - some practical modifications of the haemoquant assay for haemoglobin in faeces. Clin. Chem. Acta. 169:1987;319-322.
37. Wild D. The immunoassay handbook. 1994;Stockton Press, New York.
38. Young G.P., StJohn J.B. Faecal occult blood tests: Choice, usage and clinical applications. Clin. Biochem. Rev. 13:1992;161-167.